NDAINJECTIONINJECTABLE
Approved
Jun 1941
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THEELIN (estrone) is an injectable estrogen replacement therapy approved in 1941 for hormone deficiency indications. As a small-molecule estrogen, it works by binding estrogen receptors to restore hormonal balance in patients with insufficient endogenous estrogen production. This legacy product represents one of the earliest hormone therapies in modern pharmaceutical history.
LOE Approaching
Minimal commercial opportunity; legacy product with declining market relevance and likely small brand support team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
THEELIN offers no meaningful career advancement opportunity; associated roles are maintenance-focused positions managing a legacy asset with minimal growth potential. Professionals assigned to this product should expect limited visibility, budget, and strategic importance within the organization.
Product Manager (Legacy Portfolio)Regulatory Affairs (Compliance)
Worked on THEELIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.